- Home
- HOUR vs BTAI Comparison
HOUR vs BTAI Comparison
Compare HOUR & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOUR | BTAI |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.3M | 49.2M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HOUR | BTAI |
|---|---|---|
| Price | $2.04 | $2.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 106.3K | ★ 661.6K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $140,790,433.00 | $752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $416.40 |
| P/E Ratio | $85.48 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.10 | $1.17 |
| 52 Week High | $6.90 | $9.26 |
Technical Indicators
Market Signals| Indicator | HOUR | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 48.38 | 51.76 |
| Support Level | $2.01 | $1.82 |
| Resistance Level | $2.24 | $2.33 |
| Average True Range (ATR) | 0.12 | 0.17 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 56.25 | 62.87 |
Price Performance
Historical ComparisonAbout HOUR Hour Loop Inc.
Hour Loop Inc is a technology-enabled consumer products company that uses machine learning and data analytics to design, develop, market, and sell products. Hour Loop predominantly operates through online retail channels such as Amazon, Walmart, and Hourloop.com. The Company, as an Internet marketplace seller, sells products in multiple categories, including home/garden decor, toys, kitchenware, apparel, and electronics. It has only one segment, which is online retail (e-commerce).
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.